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Dear Editor, 
 Please find enclosed a manuscript entitled "Anti-allodynic effects of systemic inhibitors of 
Acid-Sensing Ion Channels 1 (ASIC1) against acute and chronic migraine in rodents” by 
C. Verkest, E. Piquet, S. Diochot, M. Dauvois, M. Lanteri-Minet, E Lingueglia and A Baron, that 
we are submitting for publication in British Journal of Pharmacology. 
Acid-Sensing Ion Channels (ASICs) are voltage-insensitive cation channels activated by 
extracellular acidosis, which have been proposed to be important pain detectors of sensory 
neurons in the orofacial area. This was based in large part on the use of amiloride, a non-specific 
ASIC blocker, which showed beneficial effects in animal models of migraine and in patients in a 
pilot open clinical study. 
In this paper, we focused on cutaneous allodynia, a hallmark of migraine especially in its 
chronic form, which is highly disabilating, difficult to treat, and affect both cephalic and extra-
cephalic regions. We explored the involvement of the ASIC1-subtype in these symptoms by 
combining amiloride and mambalgin-1, a peptide sp cifically blocking ASIC1-containing channels. 
We show that i.v. injection of these compounds reverse acute and chronic cutaneous allodynia not 
only in extra-cephalic territories as usually assessed, but also in cephalic ones, in a rodent model 
of migraine induced by systemic injection of the nitric oxide donor isosorbide dinitrate (ISDN). 
The anti-allodynic effects were not altered in ASIC1a-knock-out mice, suggesting a prevailing 
contribution of sensory neuron-specific ASIC1b-containing channels. They are comparable to the 
ones of the anti-migraine drug sumatriptan and of the preventive drug topiramate on acute and 
chronic allodynia, respectively. Mambalgin-1 also exerts a prophylactic effect on the development 
of chronic allodynia upon daily inter-attack injection. Our findings therefore support a role for 
peripheral ASIC1-containing channels in migraine cutaneous allodynia as well as in its 
chronification, and demonstrate the therapeutic potential of systemic ASIC1-specific inhibitors for 
both acute and prophylactic treatment of migraine and headaches. 
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Abstract  
Background and purpose 
Acid-Sensing Ion Channels (ASICs) are neuronal proton sensors emerging as potential 
therapeutic targets in pain of the orofacial region. Amiloride, a non-specific ASIC blocker, has been 
shown to exert beneficial effects in animal models of migraine and in patients. We explored the 
involvement of the ASIC1-subtype in cutaneous allodynia, a hallmark of migraine affecting 
cephalic and extra-cephalic regions in about 70% of migrainers. 
Experimental approach 
We investigated the effects on cephalic and extra-cephalic mechanical sensitivity of systemic 
injections of amiloride and mambalgin-1, a specific inhibitor of ASIC1a- and ASIC1b-containing 
channels, in a rodent model of acute and chronic migraine induced by intraperitoneal injections of 
isosorbide dinitrate. 
Key results 
Intravenous injection of these inhibitors reversed attack-like cephalic and extra-cephalic acute 
cutaneous mechanical allodynia in rats, inducing a delay in the subsequent establishment of chronic 
allodynia. Mambalgin-1 or amiloride also reversed established chronic allodynia. This effect was 
not altered in ASIC1a-knock-out mice, suggesting a prevailing contribution of sensory neuron-
specific ASIC1b-containing channels. Mambalgin-1 anti-allodynic effects are comparable to the 
ones of the anti-migraine drug sumatriptan and of the preventive drug topiramate on acute and 
chronic allodynia, respectively. A single daily inter-attack injection of mambalgin-1 also had 
a significant preventive effect on allodynia chronification. 
Conclusions and Implications 
These data support the involvement of ASIC1-containing channels, with possibly a major role 
of the peripheral ASIC1b subtype, in migraine cutaneous allodynia as well as in its chronification. 
They highlight the therapeutic potential of ASIC1 inhibitors in migraine for both acute and 
prophylactic treatment. 
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Abbreviations 
ASIC: Acid-sensing Ion channel 
Mamb-1: mambalgin-1 
CSD: cortical spreading depression 
TG: trigeminal 
NO: nitric oxide 
ISDN: isosorbide dinitrate 
TNC: trigeminal nucleus caudalis 
CGRP: calcitonin gene-related peptide 
i.v.: intravenous 
i.pl.: intraplantar 
i.p.: intraperitoneal 
5-HT: serotonin or 5-hyd oxy tryptamine 
KO: knock-out 
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ASIC, mambalgin, migraine, allodynia, amiloride 
 
  
Page 5 of 39
British Pharmacological Society
British Journal of Pharmacology
For Peer Review
4 
 
Introduction  
Migraine is a major contributor to public ill health (GBD 2015 Disease and Injury Incidence 
and Prevalence Collaborators. Vos T, 2016) with still poorly understood pathogenetic mechanisms 
(Goadsby et al., 2017) possibly including extracellular acidification. Cortical spreading depression 
(CSD), considered to be the neurophysiological correlate of migraine aura, could activate and 
sensitize trigeminal (TG) meningeal nociceptors (Karatas et al., 2013) through local release of 
extracellular compounds (K
+
, ATP, nitric oxyde…), dural sterile inflammation and ischemia 
associated with extracellular acidification also involving mast cells degranulation (Levy, 2009; 
Rozniecki et al., 1999). Subsequent sensitization of central pathways would cause cephalic and 
extra-cephalic cutaneous allodynia (Boyer et al., 2014; Burstein et al., 2010; Burstein et al., 2015; 
Edelmayer et al., 2009) reported by 70% of migrainers during migraine attacks (Lipton et al., 
2008). Per year, approximately 2.5% of episodic migrainers become chronic migrainers, with at 
least 15 days of headache per month (Bigal et al., 2008; Lipton et al., 2015), showing acute 
cutaneous allodynia during attacks but also interictal allodynia between them (Lovati et al., 2008; 
Zappaterra et al., 2011). Cutaneous allodynia is now considered as a marker and a risk factor for 
chronic migraine (Benatto et al., 2017; Louter et al., 2013), chronic migraine onset being increased 
by 30% among episodic migrainers, and chronic migraine persistence being increased by 15% in 
chronic migrainers (Scher et al., 2017). 
Preclinical migraine models in rodents are based on human observations. Nitric oxide (NO) 
donors such as nitroglycerin (NTG) (Ashina et al., 2013) and nitrate-based drugs with slower 
pharmacokinetics like isosorbide dinitrate (ISDN) used in the treatment of cardiovascular disease 
(Hansen et al., 2017; Iversen et al., 1992; Olesen et al., 2015), trigger a delayed-migraine attack 
associated with cutaneous facial and extra-facial allodynia (de Tommaso et al., 2004; Thomsen et 
al., 1996). In rodents, NO donors evoke elevated CGRP blood levels, meningeal inflammation, 
photo- and phonophobia, sensitization of central neurons of the trigeminal nucleus caudalis (TNC), 
cephalic and extra-cephalic allodynia, as well as spontaneous facial pain. The efficiency of 
clinically relevant treatments like sumatriptan, CGRP antagonists and antibodies, anti-inflammatory 
drugs, or prophylactic drugs like propranolol and topiramate further support the relevance of these 
animal models of migraine (Bates et al., 2010; Farkas et al., 2016; Goadsby et al., 2017; Harris et 
al., 2017; Jansen-Olesen et al., 2013; Pradhan et al., 2014; Schytz et al., 2017). Effects of systemic 
ISDN injections were recently described in rats, with a facilitation of C-fiber-evoked responses in 
50% of second-order central neurons (Dallel et al., 2017; Flores Ramos et al., 2017), leading to 
cutaneous pain sensitization.  
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Acid-Sensing Ion Channels (ASICs) are voltage-insensitive cation channels activated by 
extracellular acidosis (ASIC1-3) (Waldmann et al., 1997) and lipids (ASIC3) (Marra et al., 2016). 
They are widely expressed throughout the peripheral and central nervous system where they have 
been implicated in various pathophysiological processes including pain (Deval et al., 2015). 
Most subunits are expressed in TG neurons, where ASIC1- and ASIC3-containing channels can 
contribute to activation of meningeal afferents (Yan et al., 2011; Yan et al., 2013) and in migraine 
pathophysiology (Dussor, 2015). ASIC1a and 2a are expressed by second-order neurons of the TNC 
(Cho et al., 2015), and brain ASIC1a-containing channels have been implicated in CSD (Holland et 
al., 2012). 
Peptide toxins from animal venoms specifically targeting different ASIC subtypes have been 
instrumental to reveal their roles in pain (Baron et al., 2013; Bohlen et al., 2011; Deval et al., 2008; 
Mazzuca et al., 2007), including mambalgins that exert potent analgesic effects against acute, 
inflammatory and neuropathic pain through specific inhibition of ASIC1a- and/or ASIC1b-
containing channels (Diochot et al., 2016; Diochot et al., 2012). Using mambalgin-1 (Mamb-1) in 
combination with amiloride, a non-specific ASICs blocker, we explored here the involvement of 
ASIC1-containing channels in mechanical cephalic and extra-cephalic cutaneous allodynia in the 
ISDN-induced model of migraine in rodents.  
 
Methods  
Animals 
 Experiments were performed on male Sprague Dawley rats (Janvier Labs) weighting 250 to 
400g (mean weight: 306 ± 12g, 6 to 9 weeks old), and on male C57BL/6J wild-type (Charles River 
Laboratories) and ASIC1a-knock-out mice (Wemmie et al., 2002) of 7-13 week-old weighting 20-
25g. Animals were housed in a 12 hours light-dark cycle with food and water available ad libitum. 
Animal procedures were approved by the Institutional Local Ethical
 
Committee and authorized the 
French Ministry of Research according to the European Union regulations and the Directive 
2010/63/EU (Agreements C061525 and 01550.03). Animals were sacrificed at experimental end 
points by CO2 euthanasia. 
 
Drugs and in vivo injections 
Synthetic Mamb-1, showing the same pharmacological activity than native peptide, was 
purchased from Synprosis/Provepep (Fuveau, France), Smartox (Saint Martin d’Hères, France), or 
obtained from Commissariat à l’Energie Atomique, iBiTecS, Service d’Ingénierie Moléculaire des 
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Protéines (Gif sur Yvette, France) (Mourier et al., 2016). The biological activity of all synthetic 
Mamb-1 batches was validated on heterologously expressed recombinant ASIC channels.  
Mamb-1 was dissolved in vehicle solution containing NaCl 0.9% and bovine serum albumin 
0.05% to prevent non specific toxin adsorption. For intravenous (i.v.) injections in rats, Mamb-1 
(11.3 nmole/kg, i.e., 200 µl of 16.5 µM for a 300g rat), amiloride hydrochloride hydrate (10 mg/kg, 
i.e., 200 µl of 56 mM for a 300g rat, Sigma Aldrich), topiramate (30 mg/kg, i.e.,  500 µl of 18mg/ml 
for a 300g rat, Selleckchem), all dissolved in vehicle solution, or sumatriptan succinate (10 mg/kg 
i.e., 250 µl of injectable 12 mg/ml solution for a 300g rat, Imiject®, GlaxoSmithKline) were 
injected in the caudal vein of conscious rats (restrained in a cylinder) with a 30G needle. 
For intraplantar subcutaneous (i.pl.) injections, Mamb-1 (6.7 nmole/kg, i.e., 50 µl of 41 µM for a 
300g rat) was injected in the left hindpaw of conscious rats with a 26G needle. For mice, Mamb-1 
(13.6 nmole/kg, i.e., 200 µl of 1.7 µM for a 25g mouse) dissolved in vehicle solution was i.v. 
injected in the caudal vein of conscious mice (restrained in a cylinder) with a 30G needle. 
 
Thermal and mechanical sensitivity measurements 
Thermal sensitivity was assessed using the Hargreaves plantar test (Ugo Basile, Italy). 
Unrestrained rats were placed in individual plastic boxes on a glass floor. The withdrawal latency 
(s) of the rat hindpaw exposed to an infrared source (intensity of 190 ±1 mW/cm²) was measured in 
triplicate with at least 1min between two stimulations, and the mean latency was calculated. A cut-
off period of 20s was used to avoid potential tissue damage. Rats were trained 2 days before 
experiments. To test the effect of Mamb-1, thermal sensitivity was measured every 15 minutes 
before (basal value) and during two hours after Mamb-1 or vehicle injection. 
The face mechanical sensitivity was measured using calibrated von Frey filaments (Bioseb, 
France). Unrestrained rats placed in individual plastic boxes on top of a wire surface boxes were 
trained over one week to stimulation on the periorbital area, following a progressive protocol, 
starting with non-noxious filaments during the first 3 days of training. The face withdrawal force 
threshold (g) was determined by the filament evoking at least 3 responses over five trials, starting 
with lower force filaments. To test the effect of ISDN, the face mechanical sensitivity was 
measured every 15 minutes before (basal value) and during three hours after intraperitoneal (i.p.) 
injection. To test the effect of Mamb-1 and other compounds, face mechanical sensitivity was 
measured every 15 minutes before (basal value) and during two hours after compound or vehicle 
injection.  
The hindpaw mechanical sensitivity was evaluated with a dynamic plantar aesthesiometer (Ugo 
Basile, Italy). Unrestrained rats were placed in individual plastic boxes on top of a wire surface. 
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The rat hindpaw was submitted to a force ramp up to 30 g during 20 s, the paw withdrawal force 
threshold (g) was measured in triplicates, and the mean force was calculated. Rats were trained 2 
days before experiments. To test the effect of ISDN, the hindpaw mechanical sensitivity was 
measured every 15 minutes before (basal value) and during three hours after intraperitoneal (i.p.) 
injection. To test the effect of Mamb-1 and other drugs, the hindpaw mechanical sensitivity was 
measured every 15 minutes before (basal value) and during two hours after injection. For mice, the 
same procedure was used, except that the mice hindpaw was submitted to a force ramp up to 7.5 g 
during of 10 s, and that the hindpaw mechanical sensitivity was measured every 30 minutes. 
 
Pain models 
Local inflammation was induced by i.pl. injection in the left hindpaw of 100 µl of 2% 
carrageenan (Sigma-Aldrich) with a 25G needle. Thermal and mechanical sensitivity were 
measured before (basal values) and 3 hours after the carrageenan injection to measure heat 
hyperalgesia and mechanical allodynia induced by inflammation (control values). Effects of drugs 
were followed by measurements every 15 min during 2 hours after their injection.  
The rat model of NO-induced migraine was induced by intraperitoneal (i.p.) injection of 
ISDN (Risordan®, Sanofi) at 10mg/kg. The cephalic and hindpaw extra-cephalic mechanical 
sensitivities were measured simultaneously on the same rat. The attack-like mechanical allodynia 
induced by a single ISDN injection was followed for 3 hours after injection. Chronic mechanical 
allodynia was induced by a single daily injection of ISDN during 4 days. Cephalic and extra-
cephalic mechanical sensitivity were measured each day before the ISDN i.p. injection. Drugs were 
tested on chronic mechanical allodynia on the 5
th
 day and effects were followed every 15 min 
during 2 hours after injection. This model has been transposed to mice according to the same 
protocol, except that only the hindpaw extra-cephalic mechanical sensitivity was measured. 
 
Data analysis 
 The power calculation was performed with an alpha value of 0.05 and a power of 0.8 with 
G*Power software, to calculate the minimum sample size per group needed depending on the 
expected variability of measurements (which differs between behavioral tests) and the type of 
statistical test to be used. For example, for rat experiments, the minimal calculated sample size was 
8 with effect sizes between 1.6 and 1.1. As most of our behavioral experiments and 
pharmacological treatments were not previously tested, and to anticipate the possible occurrence of 
non-respondent animals to pre-required treatments by carrageenan or ISDN, we set our usual 
minimal experimental sample size to 9. This “n” value refers to independent values and not includes 
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technical replicates (replicates were used to calculate a mean individual value). Control (or vehicle 
treated) animals and test animals were randomized within experimental days. Data are presented as 
mean values ± standard error of the mean (SEM). Data analysis and statistics were performed with 
Microcal Origin 6.0 and GraphPad Prism 4 softwares by two independent experimenters. 
The normality of data distribution was tested by KS normality test, D’Agostino & Pearson omnibus 
normality test and Shapiro-Wilk normality test, and parametric or non parametric tests were chosen 
for normal or non normal data distribution, respectively. Non parametric tests were used when the 
number of animals per experimental group was less than 10, because the results of normality tests 
were not fully reliable in these conditions. The statistical difference between two different 
experimental groups was analyzed by the parametric unpaired Student’s t-test or by the non 
parametric Mann-Whitney test. The statistical difference between more than two different 
experimental groups was assessed by the parametric one-way analysis of variance (Anova) followed 
by a Tukey post-test, or by the non parametric Kruskall Wallis test followed by a Dunns post-test. 
For data within the same experimental group, a parametric paired Student’s t-test or a non 
parametric Wilcoxon matched pair test were used. For behavioral experiments, kinetics of effects 
were shown, along with cumulative effect over 2 hours after injection of drugs, or over 3 hours after 
ISDN injection, calculated as Area Under the Curve (AUC, g x min for mechanical sensitivity, or s 
x min for thermal sensitivity) subtracted from the control value for each animal. 
 
Results  
Anti-allodynic effects of i.v. mambalgin-1 against inflammatory pain in rats 
Mambalgins exert analgesic effects in mice upon different routes of administration (i.pl., i.v., 
i.t.) and against different types of pain, including inflammatory pain (Diochot et al., 2016; Diochot 
et al., 2012). However, their effects in rats were never tested. Before using the ISDN-induced model 
of migraine for simultaneous measurements of cephalic and extra-cephalic mechanical sensitivity, 
we first determined the effect of Mamb-1 in inflammatory pain in rats. Three hours after i.pl. 
injection of 2% carrageenan in the hindpaw, mechanical allodynia was observed, with a decrease in 
withdrawal threshold force from 18.4 ± 0.5 down to 9.2 ± 0.2g (Fig. 1A), as well as heat 
hyperalgesia, with a decrease in withdrawal latency from 9.0 ± 0.3 down to 4.3 ± 0.2s (Fig. 1B). 
Intravenous injection of Mamb-1 induced a complete and sustained reversal of the inflammatory-
induced mechanical allodynia (Fig 1A, 19.1 ± 0.8g after 45 minutes), as well as a complete 
reversion of the inflammatory-induced heat hyperalgesia (Fig. 1B, 8.7 ± 0.5s, after 45 minutes). 
Local i.pl. injection of Mamb-1 in the rat inflamed hindpaw also resulted in a complete and 
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sustained reversal of the inflammatory-induced mechanical allodynia (Fig. 1C) and heat 
hyperalgesia (Fig. 1D). The kinetics and total effects of Mamb-1 were comparable between i.v. and 
i.pl. injections (Fig. 1C-F). Interestingly, i.pl. and i.v. injections of Mamb-1 had no effect on 
hindpaw mechanical pain threshold in naive rats (Suppl. Fig. 1). 
These data indicate that i.v. or i.pl. Mamb-1 exert anti-allodynic effects on inflammatory pain 
in rats, comparable to the effects we already described in mice that were mainly peripheral and 
caused by the inhibition of ASIC1b-containing channels (Diochot et al., 2016).  
 
Effect of i.v. mambalgin-1 and amiloride on acute cutaneous mechanical allodynia in the 
ISDN-induced model of migraine 
The ISDN-induced chronic migraine model was developed recently in rats (Dallel et al., 
2017; Flores Ramos et al., 2017), related to the chronic NTG-induced model first developed in mice 
(Pradhan et al., 2014). One i.p. injection of ISDN (10 mg/kg) induces mechanical allodynia 
mimicking that is occurring during migraine attack, with a decrease in cephalic and extra-cephalic 
mechanical sensitivity. The facial and hindpaw withdrawal force thresholds reached their minimal 
values after 1.5 hours (3.6 ± 0.2 from a basal control value of 7.8 ± 0.2g; and 12.9 ± 0.4 from a 
basal control value of 17.5 ± 0.2g, respectively) that were maintained for at least 3 hours, whereas 
i.p. injections of saline were without effect (Suppl. Fig. 2A, B, black symbols, left panels). Twenty 
four hours later, allodynia was still not fully reversed, and one ISDN injection per day during four 
days resulted in the progressive development of a chronic basal mechanical allodynia (from 7.8 ± 
0.2 to 2.4 ± 0.2g on the face, and from 17.5 ± 0.2 to 10.3 ± 0.2g on the paw; Suppl. Fig. 2C, D), 
which was correlated with a progressive decrease in the ISDN-induced attack-like cephalic and 
extra-cephalic total effect on acute cutaneous allodynia, the last injection inducing no more 
significant effect (Suppl. Fig. 2A, B, right panels). The chronic basal mechanical allodynia persisted 
several days after the last ISDN injection, and a nearly total reversion was observed 15 days after 
the end of ISDN treatment (Suppl. Fig. 2C, D).  
The effect of i.v. Mamb-1 on the attack-like acute mechanical allodynia induced by the first 
ISDN injection was tested. Mamb-1 was injected after the full development of acute allodynia (i.e., 
105 min after ISDN i.p. injection). Mamb-1 induced a full reversal of facial mechanical allodynia 
(Fig. 2A), the withdrawal force increasing from the allodynic value of 3.3 ± 0.5 up to 7.6 ± 0.4g one 
hour after the i.v. injection, which is not significantly different from the baseline (8.0 ± 0.3g). 
On the same animals, Mamb-1 only induced a partial reversal of the hindpaw mechanical allodynia, 
the withdrawal force increasing from the allodynic value of 11.2 ± 0.5 up to 14.0 ± 1.3g one hour 
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after the i.v. injection (Fig. 2B). These effects were sustained for at least 2 hours. The anti-allodynic 
effect of i.v. Mamb-1, which significantly reduced the total effects of the first injection of ISDN on 
cutaneous allodynia, induced a one-day shift in the development of chronic allodynia induced by 
subsequent daily i.p. injections of ISDN in both cephalic and extra-cephalic territories, without any 
change in the maximal basal allodynia measured on the last day (Fig. 2C, D). This supports, 
as suggested in humans, a causality link between occurrence of attack-like mechanical allodynia 
and the development of chronic allodynia. 
The effect of i.v. Mamb-1 on ISDN-induced attack-like mechanical allodynia was compared 
with the one of amiloride, a well-known non-selective inhibitor of ASICs, and also with the one of 
acute migraine therapy sumatriptan, a 5-HT1B/1D receptor agonist. Amiloride or sumatriptan 
succinate, both i.v. injected in the same conditions as Mamb-1, also exerted an anti-allodynic effect. 
Amiloride induced a full reversion of face mechanical allodynia (Fig. 3A) and a partial but 
significant reversion of hindpaw allodynia (Fig. 3B), similar to the sustained Mamb-1 effects. 
As expected from its therapeutical effect, and as previously described in mice models of migraine 
(Bates et al., 2010; Pradhan et al., 2014), sumatriptan also showed sustained anti-allodynic 
properties, with a partial reversion of both facial (Fig. 3A) and hindpaw (Fig. 3B) allodynia. 
All together, these data show that systemic i.v. Mamb-1 and amiloride efficiently reverse the 
ISDN-induced, attack-like acute cephalic, and to a lesser extent extra-cephalic, mechanical 
cutaneous allodynia, with a similar, and even higher, potency than sumatriptan.  
 
Effects of i.v. mambalgin-1 and amiloride on the maximal chronic cutaneous mechanical 
allodynia in the ISDN-induced model of migraine 
 When Mamb-1 was injected one day after the last ISDN injection (i.e., on the fifth day), it 
fully reversed the maximal chronic facial mechanical allodynia (Fig. 4A), increasing the facial 
withdrawal force from 3.0 ± 0.4 up to 9.6 ± 2.1g after one hour, a value similar to baseline (8.6 ± 
0.9g). Mamb-1 also partially reversed the maximal chronic hindpaw mechanical allodynia 
(Fig. 4B), increasing the paw withdrawal force from 9.8 ± 0.2 up to 15.0 ± 1.1g after one hour, 
which is significantly different from vehicle as well as from baseline (18.0 ± 0.2g). Amiloride also 
showed similar anti-allodynic effects (Fig. 4A, B). Both compounds were as potent as topiramate, a 
clinically used preventive drug against migraine, whereas sumatriptan used in acute migraine 
therapy was ineffective (Fig. 4C-F), as previously described (Pradhan et al., 2014). Local i.pl. 
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injection of Mamb-1, which was able to reverse inflammatory-induced mechanical paw allodynia 
(Fig 1C), was without effect on ISDN-induced chronic paw mechanical allodynia (Suppl Fig. 3) 
showing that the local inhibition of ASICs in sensory neurons of the paw was not involved in the 
anti-allodynic effet of Mamb-1 on the paw ISDN-induced allodynia, contrary to the effects on 
inflammatory pain. Interestingly, the absence of effect of i.pl. injection of Mamb-1 on chronic facial 
ISDN-induced allodynia, confirmed that the effect of the peptide upon i.pl. injection remains local 
without important systemic diffusion through blood. 
 These data show that systemic i.v. Mamb-1 and amiloride efficiently reverse the maximal 
chronic cephalic and extra-cephalic chronic cutaneous mechanical allodynia with a potency similar 
to topiramate. 
 
Preventive effect of i.v. mambalgin-1 treatment on the development of chronic cutaneous 
mechanical allodynia in the ISDN-induced migraine model 
Mamb-1 was able to reverse the maximal chronic cutaneous allodynia induced by four days 
of ISDN injections. We tested next the effects of one daily i.v. injection of Mamb-1 for four days, 
between ISDN-induced attacks, and their consequences on the development of chronic allodynia.  
In good agreement with the data showing no effect of i.v. injection of Mamb-1 on basal paw 
mechanical threshold in naive rats (Suppl. Fig. 1), the i.v. injection of Mamb-1 30 minutes before 
the first i.p. injection of ISDN did not change the basal face and paw mechanical sensitivities 
(Fig. 5A, B, black symbols), nor the attack-like effect of ISDN, with the maximal allodynia 
reaching 5.3 ± 0.5 from the basal level of 8.2 ± 0.2g on the face, and 13.7 ± 0.3 from a basal level of 
18.5 ± 0.2g on the paw (Fig. 5A, B black symbols) after two hours, which was not significantly 
different from vehicle injected rats (Fig. 5C, D black symbols). A basal allodynia appeared the day 
after (i.e., on day 2; Fig 5E, F) that was reversed by Mamb-1 i.v. injected 30 minutes before the 
second ISDN injection (Fig. 5A, B red symbols), whereas vehicle was without effect (Fig. 5C, D, 
red symbols). On day 3, the basal cutaneous allodynia was significantly less pronounced in Mamb-
1-treated compared to vehicle-treated rats, reaching 5.1 ± 0.4g on the face and 14.7 ± 0.3g on the 
paw, and 2.9 ± 0.4g on the face and 13.4 ± 0.2g on the paw, respectively (Fig. 5E, F). Repeated i.v. 
injection of Mamb-1 on day 3 and 4 finally led to a significant reduction in the maximal chronic 
allodynia on day 5, i.e., 24 hours after the last ISDN injection, reaching 4.7 ± 0.3g on face and 13.8 
± 0.5g on paw, compared to 1.9 ± 0.3g and 11.5 ± 0.4g, respectively, on vehicle-treated rats 
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(Fig. 5E, F). Consequently, an ISDN-induced attack-like increase in allodynia was still observed in 
Mamb-1-treated rats on the fourth day (Fig. 5A, B, blue symbols), but not in vehicle-treated rats 
already close to the maximal allodynic level (Fig. 5C, D, blue symbols).  
Our results show that daily inter-attack i.v. injection of Mamb-1 was able to significantly 
reduce the chronic allodynia that develops upon injection of ISDN for several days, especially on 
facial territory.  
 
The anti-allodynic effect of i.v. mambalgin-1 in the ISDN-induced chronic migraine model is 
still present in ASIC1a knock-out mice 
 Since Mamb-1 inhibits ASIC1-containing channels (i.e., comprising either ASIC1a- and/or 
ASIC1b subunits), the contribution of ASIC1a to its anti-allodynic effects in the ISDN-induced 
chronic migraine model was tested on hindpaw mechanical sensitivity in ASIC1a-knock-out (KO) 
mice. In wild-type mice, the first i.p. injection of ISDN induced an acute paw allodynia, with the 
withdrawal force decreasing from 4.1 ± 0.1 down to 3.0 ± 0.1g two hours after the ISDN injection 
(Fig. 6A, black symbols). Allodynia was not fully reversed the next day, and one ISDN injection 
per day during four days resulted, like in rats, in the progressive development of a chronic 
mechanical allodynia correlated with a progressive decrease in the daily ISDN-induced attack, 
leading to the absence of effect of the fourth ISDN injection (Fig. 6A, blue symbols). On day 5 
(i.e., 24 hours after the last ISDN injection), the maximal chronic allodynia reaches 2.7 ± 0.1 from 
the control (day 1) value of 4.1 ± 0.1g and was reversed towards control mechanical sensitivity by 
an i.v. injection of Mamb-1 (Fig. 6B). Interestingly, the reversion of chronic paw allodynia was 
complete in mice, whereas only partial in rats. The same experiments have been done in ASIC1a-
KO mice and showed no difference with wild-type animals either in the ISDN-induced acute attack-
like allodynia (at day 1 and at day 4) (Fig. 6C), nor in the development of chronic allodynia 
(reaching 2.6 ± 0.1 from the control day 1 value of 4.1 ± 0.1g, not significantly different from wild-
type mice with Mann Whitney non parametric test) and in the anti-allodynic effects of i.v. Mamb-1 
on the maximal chronic allodynia (Fig. 6D). 
 
 These data show that ASIC1a is not needed for the anti-allodynic effects of Mamb-1 nor for 
establishment of the ISDN-induced migraine model in mice. They also indicate that ISDN has a 
similar effect in mice than in rats after repetitive daily injections with the establishment of a 
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maximal chronic basal allodynia, which is consistent with what was previously described with 
nitroglycerin as the NO-donor (Pradhan et al., 2014). 
 
Discussion  
In this study, we show the anti-allodynic effects of intravenous ASIC1 inhibitors in a rodent 
model of migraine induced by daily i.p. injection of ISDN, a long lasting NO-donor. Mambalgin-1 
and amiloride reverse cephalic and extra-cephalic cutaneous allodynia when i.v. injected during the 
acute attack evoked by one ISDN injection, with an effect similar to the one of sumatriptan, and 
cause a delay in the establishment of chronic allodynia induced by subsequent ISDN injections. 
ASIC1 inhibitors are also able to reverse the maximal cephalic and extra-cephalic chronic allodynia 
when i.v. injected after the four injections of ISDN, with an effect similar to the one of topiramate. 
Daily inter-attack i.v. injection of Mamb-1 is able to significantly reduce maximal cutaneous 
allodynia, thus exerting a preventive effect on the establishment of chronic allodynia. 
 
Involvement of peripheral ASIC1-containing channels in migraine-induced cutaneous 
allodynia and in its chronification. 
The contribution of ASIC1 channels in acute and chronic cutaneous allodynia in the ISDN-
induced migraine model is strongly supported by the similar anti-allodynic effects of amiloride, a 
well described non-selective inhibitor of ASICs, and Mamb-1, a specific inhibitor of ASIC1-
containing channels (Diochot et al., 2012). Mamb-1, contrary to amiloride, does not block the 
epithelial sodium channel involved in blood pressure regulation (Suppl. Fig. 4), making unlikely a 
significant indirect vascular contribution of these compounds in the ISDN-induced migraine model. 
In rodents, Mamb-1 only inhibits ASIC1a- and ASIC1b-containing channels, with ASIC1a 
expressed in both central and sensory neurons, and ASIC1b exclusively expressed in sensory 
neurons. We have previously shown that the central effects of Mamb-1 are totally lost in ASIC1a-
KO mice (Diochot et al., 2016; Diochot et al., 2012). ASIC1a is not necessary to the anti-allodynic 
effect of i.v. Mamb-1 in the ISDN-induced migraine model. This precludes a major contribution of 
central ASIC1a-containing channels and supports a peripheral effect involving ASIC1b specifically 
expressed in sensory neurons, although a direct demonstration is hampered by the lack of ASIC1b-
KO mice. However, native ASICs are composed of three identical or different subunits, and the 
contribution of peripheral ASIC1a subunit in wild-type animals cannot be ruled out, for instance 
within heteromeric channels made of ASIC1a and ASIC1b. Our results are also in good agreement 
with our previous data in mice showing a major role for peripheral ASIC1b-containing channels in 
the analgesic effect of i.v. mambalgin-1 on inflammatory pain (Diochot et al., 2016).  
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Peripheral ASIC1-containing channels in TG sensory fibers could be therefore involved in the 
pathophysiology of migraine, possibly correlated with meningeal extracellular acidification as one 
of the initiating events. Our results support the involvement of ASICs that can be activated by NO-
induced extracellular acidification (through mast cells degranulation) and further stimulated by 
inflammatory mediators and associated transduction pathways. ASIC1- and ASIC3-containing 
channels were proposed as important pain detectors in sensory neurons of the orofofacial area (Fu et 
al., 2016) notably in the dura mater. About 80% of rat dural afferents trigger action potentials at 
pH6.0, 50% at pH7.0 and 30% at pH7.1. As a consequence, an acidic pH6.0 solution applied on 
dura-mater generates sustained cephalic and extra-cephalic allodynia, which is maximal after 2 
hours and inhibited by amiloride but not TRPV1 antagonists, supporting the involvement of ASICs 
activation in migraine-related behavior in vivo (Yan et al., 2011; Yan et al., 2013). ASIC3-
containing channels have been proposed to be involved in these effects (Yan et al., 2013), as well as 
in the potentiating effects of inflammatory factors, but our data now also support the involvement of 
ASIC1-containing channels (presumably ASIC1b) since Mamb-1 does not inhibit ASIC3-
containing channels (Diochot et al., 2012). In addition to ASIC3-containing channels, which are 
expressed in 80% of pH-sensitive dural fibers (Yan et al., 2013), the ASIC1a, ASIC1b and ASIC2 
subunits were also present in TG neurons (Cho et al., 2015; Flegel et al., 2015; Fu et al., 2016; 
Manteniotis et al., 2013), and data obtained with ASIC1a-KO mice support the involvement of 
ASIC1-like currents in TG ganglion in orofacial inflammatory pain (Fu et al., 2016). Transcriptome 
analyses recently showed higher expression of ASIC1 in TG versus lumbar DRG neurons (Lopes et 
al., 2017). Another interesting point concerns the NO potentiation of ASICs in heterologous 
systems as well as in rat sensory neurons (Cadiou et al., 2007), with transient effects on ASIC1a, 
ASIC2a and ASIC3 currents, but an irreversible effect on rat ASIC1b current that could also 
contribute to the role of ASIC1b in the ISDN-induced model. 
 Inhibition of peripheral ASIC1-containing channels in TG afferents by systemic Mamb-1 
and amiloride could thus participate in the analgesic effects seen in the ISDN-induced rat migraine 
model. Local i.pl. injection of Mamb-1 in the paw was not able to reverse ISDN-induced chronic 
paw mechanical allodynia, whereas it fully reversed the inflammatory-induced one. The systemic 
extra-cephalic, anti-allodynic effect of Mamb-1 would thus not be due to local inhibition of 
peripheral sensory ASIC1-containing channels in the paw, but would rather be a consequence of the 
reversion of cephalic ISDN-induced allodynia through inhibition of ASIC1-containing channels in 
TG sensory fibers. Peripheral sensitization of the TG sensory neurons leads to secondary central 
sensitization of the second order neurons of the TNC and upper cervical spinal cord (C1-C2), thus 
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causing subsequent cephalic allodynia, whereas extra-cephalic allodynia would reflect the further 
extension of central sensitization to upper central pain relays (like thalamus), particularly during the 
settlement of a chronic state (Boyer et al., 2014). Highly diffusible NO is also able to directly exert 
central effects, with modulation of medullary dorsal horn neurons (Flores Ramos et al., 2017), TNC 
neurons, and VPM thalamus neurons (Goadsby et al., 2017), thus amplifying cutaneous pain 
sensitization and leading to NO-induced delayed migraine headache. The anti-allodynic and anti-
chronification effects of ASIC1 inhibitors are weaker on extra-cephalic than on cephalic allodynia 
in our experiments in rats. Similar incomplete effects were reported for amiloride in another rat 
migraine model with a direct dural acidic stimulation (Yan et al., 2013) and in a mice NTG-induced 
model of chronic migraine (Tipton et al., 2015), cephalic allodynia being not assessed in both 
studies. The complete reversibility of cephalic allodynia by ASIC1 inhibitors that we observed 
would suggest that sensitization of the TNC and the upper cervical dorsal horn could depend 
directly on the activity of ASIC1-containing channels expressed in TG sensory neurons, whereas 
extra-cephalic allodynia would be partially independent of them, involving ASIC-independent 
effects of NO on paw sensory fibers (Ferrari et al., 2016) or central mechanisms independent of TG 
fibers activation (Bernstein et al., 2012).  
 
Systemic ASIC1 blockers against migraine 
Treatment of migraine, and particularly chronic migraine, remains challenging, and most of 
the therapeutic drugs are non specific, sometimes inefficient, with numerous side effects and contra-
indications (Schytz et al., 2017; Serrano et al., 2015). Cutaneous allodynia in chronic migraine is 
associated with inadequate outcomes for any anti-migraine medication (Lipton et al., 2017). 
Furthermore, a significant proportion of chronic migraine cases are due to anti-migraine medication 
abuse or misuse (Bigal et al., 2009; Lipton et al., 2015), highlighting the need of new medications, 
including new prophylactic approaches to prevent the chronification process.  
We show that i.v. amiloride and mambalgin-1 both exert anti-allodynic effects against acute 
and chronic cutaneous allodynia in the ISDN-induced migraine model, not only in extra-cephalic 
territories as usually assessed but also in cephalic ones, and that i.v. mambalgin-1 is able to exert a 
prophylactic effect on the development of chronic allodynia. This supports systemic ASIC1 
inhibitors as new potential therapeutic leads against migraine and headaches and this is in good 
agreement with data showing that a preventive daily therapy with i.p. amiloride in mice partially 
reduce acute NTG-induced as well as chronic basal mechanical paw hypersensitivity (Tipton et al., 
2015). A pilot open clinical study has also shown that systemic treatment with amiloride reduced 
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aura and headache symptoms in four of seven patients with intractable aura (Holland et al., 2012). 
Drawback of amiloride, which is used in humans as a diuretic and antihypertensive, is a poor 
specificity, and our data suggest that more specific ASIC1 blockers like mambalgin-1 could also be 
used 1) to relieve migraine attack, with benefits on subsequent chronification, 2) to relieve 
established chronic allodynia, and 3) as a preventive treatment against chronification. 
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Figure legends 
Fig. 1: Reversion of inflammation-induced paw mechanical allodynia and heat hyperalgesia 
by intravenous and local intraplantar injections of mambalgin-1 in rats. 
A, C -Full reversion by i.v. (A) and by i.pl. (C) Mamb-1 (11.3 and 6.7 nmole/kg, respectively) of 
paw inflammatory mechanical allodynia (carrageenan 2%, 3h). Paw mechanical withdrawal force 
(g), mean ± SEM, n=9, * p<0.05, ** p<0.01, *** p<0.001 with Mann Whitney non parametric test 
compared to vehicle. B, D - Full reversion by i.v. (B) and i.pl. (D) Mamb-1 of paw inflammatory 
heat hyperalgesia (carrageenan 2%, 3h). Paw withdrawal latency (s), mean ± SEM, n=9, * p<0.05, 
** p<0.01, *** p<0.001 with Mann Whitney non parametric test compared to vehicle, # p<0.05, 
## p<0.01, ### p<0.001 with Wilcoxon matched paired test compared to non inflamed basal value. 
E, F -Total effect of i.v. and of i.pl. Mamb-1 on paw mechanical withdrawal force calculated as the 
Area Under Curve (AUC) (E) and on heat paw withdrawal latency (F) calculated as the AUC 
during 2 hours after the injection. Mean ± SEM, n=9, respectively. * p<0.05, ** p<0.01, 
*** p<0.001, ns not significant compared to vehicle with Mann Whitney non parametric test.  
 
Fig. 2: Reversion of ISDN-induced, attack-like cephalic and extra-cephalic acute mechanical 
allodynia by an intravenous injection of mambalgin-1.  
A, B - Left panels - Kinetics of the anti-allodynic effect on face (A) and paw (B) mechanical 
withdrawal thresholds (g) of an i.v. injection of Mamb-1 (11.3 nmole/kg) 105 minutes after the i.p. 
injection of ISDN in rats. Mean ± SEM, n = 9. * p<0.05, ** p<0.01, *** p<0.001 with Mann 
Whitney non parametric test compared to vehicle; # p<0.05, ## p<0.01, ### p<0.001 with Wilcoxon 
matched paired test compared to control value before ISDN injection. Right panels - Total effect of 
i.v. Mamb-1 (or vehicle) on face (A) and paw (B) withdrawal force calculated as the Area Under 
Curve (AUC) during 2 hours after the i.v. injection. Mean ± SEM, n = 9. * p<0.05, ** p<0.01, 
*** p<0.001 compared to vehicle with Mann Whitney non parametric test. C, D - One i.v. injection 
of Mamb-1 (11.3 nmole/kg) after the first ISDN injection, as shown in A and B, induces a delay in 
the subsequent settlement of ISDN-induced chronic allodynia induced by three more daily ISDN 
injections. Basal face (C) and paw (D) mechanical withdrawal force (g) measured before each daily 
ISDN injection and the day after the last ISDN injection (day 5). Mean ± SEM, n = 9. * p<0.05, 
** p<0.01, *** p<0.001 with Mann Whitney non parametric test compared to vehicle; # p<0.05, ## 
p<0.01, ### p<0.001 with Wilcoxon matched paired test compared to control before the first ISDN 
injection. 
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Fig. 3: Comparison of the anti-allodynic effects of mambalgin-1, amiloride and sumatriptan 
on ISDN-induced, attack-like cephalic and extra-cephalic acute mechanical allodynia. 
A, B Left panels - Kinetics of the analgesic effects on face (A) and paw (B) mechanical withdrawal 
force (g) of amiloride (10 mg/kg) and sumatriptan succinate (Imiject©, 10 mg/kg) i.v. injected 105 
minutes after the injection of ISDN measured on the same rats. Mean ± SEM, n = 9. * p<0.05, 
** p<0.01, *** p<0.001 with non-parametric Kruskal-Wallis and Dunn’s post hoc tests compared to 
vehicle; # p<0.05, ## p<0.01, ### p<0.001 with Wilcoxon matched paired test compared to control 
value before ISDN injection. For clarity, only vehicle (same data as in Fig. 2A, B) but not Mamb-1 
is shown. Right panels - Total effect of vehicle, Mamb-1, amiloride and sumatriptan on face (A) 
and paw (B) withdrawal force calculated as the Area Under Curve (AUC) during 2 hours after 
injection. Mean ± SEM, n = 9. * p<0.05, ** p<0.01, *** p<0.001 with Mann Whitney non 
parametric test compared to vehicle; # p<0.05, ## p<0.01, ### p<0.001 with Mann Whitney non 
parametric test compared to Mamb-1. 
 
Fig. 4: Reversion of ISDN-induced maximal cephalic and extra-cephalic chronic mechanical 
allodynia by an intravenous injection of mambalgin-1.  
A-D - Kinetics of the anti-allodynic effect of Mamb-1 (11.3 nmole/kg), amiloride (10 mg/kg), 
sumatriptan succinate (Imiject©, 10 mg/kg) and topiramate (30 mg/kg), i.v. injected one day after 
the last ISDN injection (i.e., on day 5) on face (A, C) and paw (B, D) mechanical withdrawal force 
(g) in rats. The basal mechanical withdrawal force (g) was measured before each daily ISDN 
injection (left side of the y axe), showing the chronification process of cutaneous allodynia day after 
day. For clarity, kinetics were split into two graphs, sharing the same data for vehicle. Mean ± 
SEM, n = 9 except with topiramate (n=11). * p<0.05, ** p<0.01, *** p<0.001 with Mann Whitney 
non parametric test compared to vehicle; # p<0.05, ## p<0.01, ### p<0.001 with Wilcoxon matched 
paired test compared to control value before the first ISDN injection (day 1). E, F - Total effect on 
face (E) and paw (F) withdrawal force calculated as the Area Under Curve (AUC) during 2 hours 
after the i.v. injection for each rat. Mean ± SEM, n = 9. * p<0.05, ** p<0.01, *** p<0.001 with 
Mann Whitney non parametric test compared to vehicle; # p<0.05, ## p<0.01, ### p<0.001 with 
Mann Whitney non parametric test compared to Mamb-1.  
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Fig. 5: Preventive effect of i.v. Mamb-1 treatment on chronification of cephalic and extra-
cephalic mechanical allodynia in the rat ISDN-induced model of migraine.  
A-D - Kinetics of the acute effects of a daily i.v. injection of Mamb-1 (11.3 nmole/kg, A, B) or 
vehicle (C, D) 30 min before each daily ISDN injection (10 mg/kg) on face (A, C) and paw (B, D) 
mechanical withdrawal threshold (g). Mean ± SEM, n = 9. * p<0.05, ** p<0.01, *** p<0.001 with 
Mann Whitney non parametric test compared to vehicle. # p<0.05, ## p<0.01, ### p<0.001 with 
Wilcoxon matched paired test compared to baseline value before any injection. E, F - Kinetics of 
the chronic effects of a daily i.v. injection of Mamb-1 or vehicle (same conditions as in A-D) on 
basal face (E) and paw (F) mechanical withdrawal force threshold (g) measured on the same rats 
before each daily injections and after the last fourth ISDN injection (day 5). Mean ± SEM, n = 9. 
* p<0.05, ** p<0.01, *** p<0.001 with Mann Whitney non parametric test compared to vehicle, 
# p<0.05, ## p<0.01, ### p<0.001 with Wilcoxon matched paired test compared to control before 
injection. 
 
Fig.6: Reversion of ISDN-induced maximal extra-cephalic chronic mechanical allodynia by an 
intravenous injection of mambalgin-1 in wild-type and ASIC1a knock-out mice.  
A, C- Kinetics of the effects of the first ISDN injection on day 1 and of the fourth ISDN injection 
on day 4 on hindpaw mechanical withdrawal threshold (g) of wild-type (A, n=20) and ASIC1a-KO 
(C, n=17) mice. Mean ± SEM, # p<0.05, ## p<0.01, ### p<0.001 with Wilcoxon matched paired 
test compared to control value before the ISDN injection. B, D- Kinetics of the anti-allodynic effect 
of Mamb-1 (13.6 nmole/kg) and vehicle i.v. injected one day after the last ISDN injection (i.e., on 
day 5) on paw mechanical withdrawal force (g) of wild-type (B, n=10) and ASIC1a-KO (D, n=8-9) 
mice. The basal mechanical withdrawal force (g) was measured before each daily ISDN injection 
(left side of the y axe), showing the chronification process of cutaneous allodynia day after day. 
Mean ± SEM, n = 8-10. * p<0.05, ** p<0.01, *** p<0.001 with Mann Whitney non parametric test 
compared to vehicle; # p<0.05, ## p<0.01, ### p<0.001 with Wilcoxon matched paired test 
compared to control value before the first ISDN injection (day 1). Mice used in A and C have been 
then divided in half to be injected with either vehicle or Mamb-1, as shown in B and D. 
 
Appendices: Supplementary figure legends 
Supplementary Fig. 1: Absence of effect of intravenous and local intraplantar injections of 
mambalgin-1 on paw mechanical sensitivity of naive rats. 
A, B - Effect of i.v. (A) and i.pl. (B) Mamb-1 on paw mechanical sensitivity. Paw mechanical 
withdrawal force (g), mean ± SEM, n=7-14, * p<0.05, ** p<0.01, *** p<0.001 with Mann Whitney 
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non parametric test compared to vehicle. C, -Total effect of i.v. and of i.pl. Mamb-1 on paw 
mechanical withdrawal force calculated as the Area Under Curve (AUC) during 2 hours after the 
injection. Mean ± SEM, * p<0.05, ** p<0.01, *** p<0.001, ns not significant compared to vehicle 
with Mann Whitney non parametric test. 
 
Supplementary Fig. 2: Migraine-like, ISDN-induced cephalic and extra-cephalic acute and 
chronic mechanical allodynia.  
A, B - Left panels - Kinetics of the effects of each of the four consecutive daily i.p. injections of 
the ISDN (10 mg/kg) or of saline control on the face mechanical withdrawal threshold measured 
with von Frey filaments (A) and on the hindpaw mechanical withdrawal threshold measured with 
dynamic plantar aesthesiometer (B) on the same rats. Mean ± SEM, n = 6 for saline and n= 25 for 
ISDN (this n number is explained by the expected high variability and small size effect in the 
absence of preliminary data on this ISDN-induced effects in rat). * p<0.05, ** p<0.01, *** p<0.001 
with Mann Whitney non parametric test compared to saline control, # p<0.05, ## p<0.01, 
### p<0.001 with Wilcoxon matched paired test compared to basal value before injection. 
Right panels - Total effect on the same rats of each injection on face (A) and paw (B) withdrawal 
force calculated as the Area Under Curve (AUC) during 3 hours after the injection. Mean ± SEM, 
* p<0.05, ** p<0.01, *** p<0.001 with Mann Whitney non parametric test compared to saline 
control. C, D - Basal mechanical face (C) and paw (D) withdrawal force threshold (g) measured on 
the same rats before each daily injection (showing the settlement of chronic allodynia) and after the 
last fourth injection (showing the sustained effect and progressive recovery). Mean ± SEM, 
* p<0.05, ** p<0.01, *** p<0.001 with Mann Whitney non parametric test compared to saline 
control, # p<0.05, ## p<0.01, ### p<0.001 with Wilcoxon matched paired test compared to control 
before the first injection. 
 
Supplementary Fig. 3: Absence of effect of intraplantar injection of mambalgin-1 on ISDN-
induced cephalic and extra-cephalic chronic mechanical allodynia.  
Kinetics of the effect of the local i.pl. injection of Mamb-1 (6.7 nmole/kg) one day after the last 
ISDN injection (i.e., on day 5) on face (A) and paw (B) mechanical withdrawal force (g) measured 
on the same rats (n=9). The basal mechanical withdrawal force (g) was measured before each daily 
ISDN injection (left side of the y axe), showing the chronification process of cutaneous allodynia 
day after day. Mamb-1 effect was not significantly different (p>0.05) from vehicle (Mann Whitney 
non parametric test). 
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Suppl. Fig. 4: Mambalgin-1 does not inhibit the epithelial sodium channel. 
cDNAs of the α, β and γ subunits of the epithelial sodium channel (ENaC, 10 ng/µl each), were co-
injected into Xenopus oocytes (oocytes preparation and cDNA injections as previously described 
(Besson et al., 2017)), and oocytes were kept during two days at 19°C in ND96 solution where Na
+
 
has been replaced by NMDG.  
A, Original traces of ENaC current recorded in Na
+
-containing ND96 during voltage-steps from 0 
to -80 mV every 10 s, in control condition and after application of either Mamb-1 
(3µM, a concentration that inhibits ASIC channels by 70 to 100% (Diochot et al., 2012)) or 
amiloride (10µM). Dotted line: zero current level. B, ENaC current (% of control current amplitude) 
was blocked by amiloride as expected (inhibition of 77 ± 5%) but was not inhibited by Mamb-1 
(2 ± 0.9%). Mean ± SEM, n=8, ** p<0.01 with Wilcoxon matched paired non parametric test. 
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